Joe specializes in providing guidance and direction to healthcare companies with respect to reimbursement and health economics for medical technologies. His experience draws from building market-access programs and value-based healthcare, and communicating health economic benefits to key stakeholders. Prior to joining NAMSA, Joe held several commercial roles focused on B2B and B2C medtech sales and marketing, global reimbursement, market access, health economics, strategy and business development. He has held leadership positions at multi-national medical device enterprises, as well as start-up companies. He also maintains a position as an Adjunct Instructor at the University of Southern California Price School of Public Policy (Los Angeles, CA).
- Global reimbursement and health economic strategy
- Commercialization and market access for medical technologies and services
- Value-based healthcare agreements, risk sharing and alternative payment models
- Health policy and payment—Medicare, Medicaid and commercial insurance
- Clinical trial design and health economic methods
- Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology (CPT) codes for medical technologies
- Economic value synthesis
- Revenue cycle and field reimbursement
- Medtech sales channels and strategic accounts
- Organizational development for Health Economics and Outcomes Research (HEOR)/Health Economics and Reimbursement (HE&R)
- Healthcare delivery quality systems
- Type 2 Diabetes management in primary care: The Role of Retrospective, Professional Continuous Glucose Monitoring. Diabetes Spectr. 2018 Aug; 31(3):279-287. Shrivastav M, Gibson W, Shrivastav R, Elzea K, Khambatta C, Sonawane R, Sierra JA, Vigersky R. PMID: 30140145; PMCID: PMC6092883.
- Clinical and economic benefits of professional CGM among people with type 2 diabetes in the United States: analysis of claims and lab data. J Med Econ. 2018 Mar; 21(3):225-230. Sierra JA, Shah M, Gill MS, Flores Z, Chawla H, Kaufman FR, Vigersky R. PMID: 28994334.
- Economic impact of hypoglycemia among insulin-treated patients with diabetes. J Med Econ. 2016 Nov; 19(11):1099-1106. Sussman M, Sierra JA, Garg S, Bode B, Friedman M, Gill M, Kaufman F, Vigersky R, Menzin J. PMID: 27292016.